The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.
VISTA
cancer
immune checkpoints
immune-resistance
immunotherapy
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
03
2021
accepted:
29
04
2021
entrez:
7
6
2021
pubmed:
8
6
2021
medline:
25
2
2023
Statut:
epublish
Résumé
Immune checkpoints (ICs) have pivotal roles in regulating immune responses. The inhibitory ICs in the tumor microenvironment (TME) have been implicated in the immune evasion of tumoral cells. Therefore, identifying and targeting these inhibitory ICs might be critical for eliminating tumoral cells. V-domain immunoglobulin suppressor of T cell activation (VISTA) is a novel inhibitory IC that is expressed on myeloid cells, lymphoid cells, and tumoral cells; therefore, VISTA can substantially regulate innate and adaptive anti-tumoral immune responses. Besides, growing evidence indicates that VISTA blockade can enhance the sensitivity of tumoral cells to conventional IC-based immunotherapy, e.g., cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors. In this regard, the current study aimed to review the current evidence about the structure and expression pattern of VISTA, its role in TME, the clinicopathological significance of VISTA, and its prognostic values in various cancers. Besides, this review intended to collect the lessons from the recent pre-clinical and clinical studies and propose a strategy to overcome tumor immune-resistance states.
Identifiants
pubmed: 34093577
doi: 10.3389/fimmu.2021.676181
pmc: PMC8172140
doi:
Substances chimiques
B7 Antigens
0
Immune Checkpoint Inhibitors
0
VSIR protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
676181Informations de copyright
Copyright © 2021 Hosseinkhani, Derakhshani, Shadbad, Argentiero, Racanelli, Kazemi, Mokhtarzadeh, Brunetti, Silvestris and Baradaran.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Mol Sci. 2013 Jun 27;14(7):13482-96
pubmed: 23807506
Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1692-1697
pubmed: 30635425
Cell Mol Immunol. 2018 Sep;15(9):838-845
pubmed: 28479600
Life Sci. 2020 Sep 1;256:118005
pubmed: 32593711
Histopathology. 2019 Sep;75(3):421-430
pubmed: 31013360
J Cancer. 2021 Jan 1;12(4):965-975
pubmed: 33442396
Sci Rep. 2020 Sep 16;10(1):15171
pubmed: 32938950
J Biol Chem. 2015 Oct 2;290(40):24267-77
pubmed: 26269601
Oral Oncol. 2016 Jun;57:54-60
pubmed: 27208845
BMC Cancer. 2018 May 2;18(1):511
pubmed: 29720116
Curr Opin Biotechnol. 2016 Aug;40:41-48
pubmed: 26938687
Clin Exp Immunol. 2020 May;200(2):120-130
pubmed: 31930484
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Clin Cancer Res. 2018 Apr 1;24(7):1562-1573
pubmed: 29203588
Cell Stem Cell. 2016 Jan 7;18(1):104-17
pubmed: 26748757
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1574-9
pubmed: 25519928
Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14846-51
pubmed: 25267631
Sci Transl Med. 2019 Dec 11;11(522):
pubmed: 31826980
Int J Oncol. 2020 Jul;57(1):237-248
pubmed: 32468013
Protein Cell. 2019 Nov;10(11):840-845
pubmed: 31236852
J Immunother. 2021 Jan;44(1):22-28
pubmed: 33086339
Immunity. 1994 Aug;1(5):405-13
pubmed: 7882171
Immunology. 2019 Jan;156(1):74-85
pubmed: 30220083
Sci Rep. 2017 May 3;7(1):1485
pubmed: 28469254
Immunobiology. 2020 Mar;225(2):151875
pubmed: 31812343
Cancers (Basel). 2019 Jul 04;11(7):
pubmed: 31277479
Front Immunol. 2020 Oct 29;11:563044
pubmed: 33250890
Sci Rep. 2020 Sep 1;10(1):14372
pubmed: 32873829
Cancer Res. 2014 Apr 1;74(7):1924-32
pubmed: 24691993
J Immunol. 2011 Aug 15;187(4):1537-41
pubmed: 21768399
Pancreas. 2018 Jul;47(6):725-731
pubmed: 29771768
PLoS One. 2014 Oct 03;9(10):e109103
pubmed: 25279955
Oncoimmunology. 2020 Oct 20;9(1):1830524
pubmed: 33150045
J Exp Med. 2011 Mar 14;208(3):577-92
pubmed: 21383057
Cancer Immunol Immunother. 2020 Oct;69(10):1989-1999
pubmed: 32393998
Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1648-1657
pubmed: 31919279
J Clin Oncol. 2011 Dec 20;29(36):4828-36
pubmed: 22042955
J Immunol. 1995 Jan 1;154(1):97-105
pubmed: 7527824
Cancer Immunol Immunother. 2020 Jul;69(7):1237-1252
pubmed: 32166404
Mod Pathol. 2017 Dec;30(12):1666-1676
pubmed: 28776578
Cancer Immunol Res. 2019 Sep;7(9):1497-1510
pubmed: 31340983
Curr Opin Pharmacol. 2017 Aug;35:40-47
pubmed: 28577499
Oncoimmunology. 2019 Feb 27;8(5):e1581546
pubmed: 31069143
Nat Med. 2017 May;23(5):551-555
pubmed: 28346412
Br J Cancer. 2019 Jan;120(1):115-127
pubmed: 30382166
FASEB J. 2012 Oct;26(10):3957-68
pubmed: 22751012
J Exp Clin Cancer Res. 2019 Aug 20;38(1):364
pubmed: 31429779
Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361-375
pubmed: 30886395
Int J Mol Sci. 2020 Nov 05;21(21):
pubmed: 33167514
Mol Cancer. 2018 Aug 23;17(1):129
pubmed: 30139382
Cancer Res. 2018 Oct 1;78(19):5680-5693
pubmed: 30115691
PLoS One. 2013 Jun 17;8(6):e65531
pubmed: 23799023
Virchows Arch. 2018 Apr;472(4):589-598
pubmed: 29520483
Glia. 2018 Dec;66(12):2645-2658
pubmed: 30306644
Cancer Immunol Immunother. 2017 May;66(5):627-636
pubmed: 28236118
Cancer Immunol Immunother. 2020 Aug;69(8):1437-1446
pubmed: 32266446
Sci Rep. 2020 Feb 14;10(1):2662
pubmed: 32060343
Oncoimmunology. 2017 Feb 21;6(4):e1293215
pubmed: 28507801
Cell Rep. 2019 Sep 3;28(10):2509-2516.e5
pubmed: 31484064
Oncol Lett. 2018 Sep;16(3):3465-3472
pubmed: 30127950
Nature. 2019 Oct;574(7779):565-570
pubmed: 31645726
Cell Rep. 2020 Jan 14;30(2):510-524.e6
pubmed: 31940493
J Clin Invest. 2014 May;124(5):1966-75
pubmed: 24743150
J Hematol Oncol. 2020 Jun 29;13(1):83
pubmed: 32600443
Science. 2020 Jan 17;367(6475):
pubmed: 31949051
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Cancer Res. 2014 Apr 1;74(7):1933-44
pubmed: 24691994
Sci Rep. 2016 Oct 10;6:34860
pubmed: 27721458
Cancer Immunol Immunother. 2018 Jul;67(7):1113-1121
pubmed: 29737375
Cancer Immunol Immunother. 2018 Nov;67(11):1685-1694
pubmed: 30128738
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2020 Jun;28(3):748-752
pubmed: 32552931
Front Immunol. 2020 Oct 15;11:580187
pubmed: 33178206
J Immunother Cancer. 2016 Dec 20;4:86
pubmed: 28031817
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Arthritis Res Ther. 2017 Dec 08;19(1):270
pubmed: 29216931
Cancer Immunol Immunother. 2020 Jan;69(1):33-42
pubmed: 31781843
J Exp Clin Cancer Res. 2019 Jun 13;38(1):255
pubmed: 31196207
Oncoimmunology. 2018 Jul 11;7(9):e1469594
pubmed: 30228937
Immunol Rev. 2017 Mar;276(1):66-79
pubmed: 28258694
Proc Natl Acad Sci U S A. 2015 May 26;112(21):6682-7
pubmed: 25964334
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373